Advice
in the absence of a submission from the holder of the marketing authorisation:
pirtobrutinib (Jaypirca®) is not recommended for use within NHSScotland.
Indication under review: as monotherapy for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) who have been previously treated with a Bruton’s tyrosine kinase (BTK) inhibitor.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice283KB (PDF)
Medicine details
- Medicine name:
- pirtobrutinib (Jaypirca)
- SMC ID:
- SMC2897
- Indication:
As monotherapy for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) who have been previously treated with a Bruton's tyrosine kinase (BTK) inhibitor
- Pharmaceutical company
- Eli Lilly and Company Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 19 January 2026